<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0186-2391</journal-id>
<journal-title><![CDATA[Acta pediátrica de México]]></journal-title>
<abbrev-journal-title><![CDATA[Acta pediatr. Méx]]></abbrev-journal-title>
<issn>0186-2391</issn>
<publisher>
<publisher-name><![CDATA[Instituto Nacional de Pediatría]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0186-23912015000600434</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Efecto sedante del midazolam genérico versus innovador en ratas Wistar]]></article-title>
<article-title xml:lang="en"><![CDATA[Sedative effect of innovative midazolam vs. generic in Wistar rats]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Alemón-Medina]]></surname>
<given-names><![CDATA[Radamés]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rivera-Espinosa]]></surname>
<given-names><![CDATA[Liliana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Zárate-Castañón]]></surname>
<given-names><![CDATA[Patricia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Flores-Pérez]]></surname>
<given-names><![CDATA[Carmen]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto Nacional de Pediatría Laboratorio de Farmacología ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Instituto Nacional de Pediatría Servicio de Terapia Intensiva ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2015</year>
</pub-date>
<volume>36</volume>
<numero>6</numero>
<fpage>434</fpage>
<lpage>441</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0186-23912015000600434&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0186-23912015000600434&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0186-23912015000600434&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN:  Antecedentes:  ocho de cada diez pacientes en Terapia Intensiva del Instituto Nacional de Pediatría no obtienen el mismo efecto ansiolíti-co y sedante con midazolam genérico (PiSA®), que con el innovador (Dormicum, Roche®) a pesar de que su biodisponibilidad es de 100%.  Objetivo:  determinar diferencias significativas en el efecto sedante del midazolam genérico y del innovador administrados parenteralmente.  Material y métodos:  estudio aleatorizado cruzado en 24 ratas Wistar macho distribuidas en 4 grupos (n=6). A cada individuo se le administró una dosis de 0.5 mg/kg de peso vía intraperitoneal. Se determinaron los grados de sedación mediante la escala de Salamone. Se midió la concentración del fármaco en las ampolletas de ambas marcas por cromatografía líquida de alta resolución.  Resultados:  el efecto sedante del midazolam apareció al mismo tiempo y tuvo la misma duración, independientemente de la marca. El efecto tiende a ser más duradero con el innovador pero sin ser estadísticamente significativo (ANOVA, p &#8804; 0.05). Asimismo, la mayoría de los animales llegaron al nivel 3 de sedación con ambas marcas.  Conclusión:  tanto el midazolam innovador como el genérico tienen el mismo efecto sedante: aparece al mismo tiempo y tiene la misma duración.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT:  Background:  Eight out of ten patients in the Intensive Care Unit of the Instituto Nacional de Pediatría do not set the same anxiolytic and sedative effect using generic midazolam (PiSA®) as with the innovative brand (Dormicum, Roche®), although its bioavailability is 100%.  Objective:  To determine significant differences in the sedative effect induced by generic and by innovative midazolam given parenterally.  Materialsand methods:  Randomised crossover study in 24 male Wistar rats allocated into 4 groups (n=6). Each individual was given a dose of 0.5 mg/kg intraperitoneally; sedation levels were determined by the scale of Salamone's scale. Drug concentration in the vials of both brands was determined by high performance liquid chromatography (HPLC).  Results:  The sedative effect of midazolam appeared at the same time for both groups and had the same duration regardless of the brand. The effect tends to be more durable with the innovative, but without statistical significance (ANOVA, p &#8804; 0.05). Likely, most animals reached Salamone's sedation level 3 with both brands.  Conclusion:  Both innovative and generic midazolam brands provide the same level of sedative effect, which appears and lasts equally.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[midazolam]]></kwd>
<kwd lng="es"><![CDATA[genérico]]></kwd>
<kwd lng="es"><![CDATA[innovador]]></kwd>
<kwd lng="es"><![CDATA[efecto sedante]]></kwd>
<kwd lng="es"><![CDATA[ratas Wistar]]></kwd>
<kwd lng="es"><![CDATA[terapia intensiva]]></kwd>
<kwd lng="en"><![CDATA[Midazolam]]></kwd>
<kwd lng="en"><![CDATA[generic]]></kwd>
<kwd lng="en"><![CDATA[innovative]]></kwd>
<kwd lng="en"><![CDATA[sedative effect]]></kwd>
<kwd lng="en"><![CDATA[Wistar rats]]></kwd>
<kwd lng="en"><![CDATA[intensive care unit]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Clinical experience with continuous intravenous sedation using midazolam and fentanyl in the paediatric intensive care unit]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hartwig]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Roth]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Theisohn]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[European Journal of Pediatrics]]></source>
<year>1991</year>
<volume>150</volume>
<page-range>784-8</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Role of GABAA receptors in sleep regulation differential effects of muscimol and midazolam on sleep in rats]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lancel]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Crönlein]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Faulhaber]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Neuropsychopharm]]></source>
<year>1996</year>
<volume>15</volume>
<page-range>63-74</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Katzung]]></surname>
<given-names><![CDATA[BG]]></given-names>
</name>
</person-group>
<source><![CDATA[Basic &amp; Clinical Pharmacology]]></source>
<year>1995</year>
<edition>10</edition>
<publisher-loc><![CDATA[New York, USA ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Midazolam pharmacology and use]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Reves]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[Fragen]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Vinik]]></surname>
<given-names><![CDATA[HR]]></given-names>
</name>
</person-group>
<source><![CDATA[Anesthesiology]]></source>
<year>1985</year>
<volume>62</volume>
<page-range>310-24</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Pharmacokinetics and bioavailability of midazolam in man]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Heizmann]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Eckert]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ziegler]]></surname>
<given-names><![CDATA[WH]]></given-names>
</name>
</person-group>
<source><![CDATA[Br J Clin Pharmacol]]></source>
<year>1983</year>
<volume>16</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>43S-9S</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[NOM-062-ZOO-1999. Especificaciones técnicas para la producción, cuidado y uso de los animales de laboratorio]]></article-title>
<source><![CDATA[Diario Oficial de la Federación]]></source>
<year>2001</year>
<publisher-loc><![CDATA[México ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Comparison between multiple behavioral effects of peripheral ethanol administration in rats Sedation, ataxia, and bradykinesia]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chuck]]></surname>
<given-names><![CDATA[TL]]></given-names>
</name>
<name>
<surname><![CDATA[McLaughlin]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Arizzi-LaFrance]]></surname>
<given-names><![CDATA[MN]]></given-names>
</name>
<name>
<surname><![CDATA[Salamone]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Correa]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Life Sci]]></source>
<year>2006</year>
<volume>79</volume>
<page-range>154-61</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Development and Validation of a Method to Quantify Midazolam in a New Oral Formulation for Pediatric Use]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Flores-Pérez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Chávez-Pacheco]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Flores-Pérez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Juárez-Olguín]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Ramírez-Mendiola]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[García-Álvarez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[González-Zamora]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Changin-Guerra]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[AJAC]]></source>
<year>2012</year>
<volume>3</volume>
<page-range>552-8</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Failure of critically ill patients to metabolize midazolam]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shelly]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[Mendel]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[GR]]></given-names>
</name>
</person-group>
<source><![CDATA[Anaesth]]></source>
<year>1987</year>
<volume>42</volume>
<page-range>619-26</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Conscious sedation for endoscopic and non-endoscopic interventional gastrointestinal procedures meeting patients expectations, missing the standard]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marriot]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Laasch]]></surname>
<given-names><![CDATA[HU]]></given-names>
</name>
<name>
<surname><![CDATA[Wilbraham]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Marriot]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[England]]></surname>
<given-names><![CDATA[RE]]></given-names>
</name>
<name>
<surname><![CDATA[Martin]]></surname>
<given-names><![CDATA[DF]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin Radiol]]></source>
<year>2004</year>
<volume>59</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>180-5</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Prolonged sedation due to accumulation of conjugated metabolites of midazolam]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bauer]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
<name>
<surname><![CDATA[Ritz]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Haberthür]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Ha]]></surname>
<given-names><![CDATA[HR]]></given-names>
</name>
<name>
<surname><![CDATA[Hunkeler]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Sleight]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Scollo-Lavizzari]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Haefeli]]></surname>
<given-names><![CDATA[WE]]></given-names>
</name>
</person-group>
<source><![CDATA[Lancet]]></source>
<year>1995</year>
<volume>345</volume>
<page-range>145-7</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Decreased plasma albumin concentration results in increased volume of distribution and decreased elimination of midazolam in intensive care patients]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vree]]></surname>
<given-names><![CDATA[TB]]></given-names>
</name>
<name>
<surname><![CDATA[Shimoda]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Driessen]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin Pharmacol Ther]]></source>
<year>1989</year>
<volume>46</volume>
<page-range>537-44</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[What changes drug metabolism in critically ill patients II. Serum inhibits the metabolism of midazolam in human microsomes]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[GR]]></given-names>
</name>
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Navapurkar]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<source><![CDATA[Anaesth]]></source>
<year>1996</year>
<volume>51</volume>
<page-range>11-5</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Pharmacokinetics of midazolam administered by continuous intravenous infusion to intensive care patients]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Malacrida]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Fritz]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Suter]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
</person-group>
<source><![CDATA[Crit Care Med]]></source>
<year>1992</year>
<volume>20</volume>
<page-range>1123-6</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Sedation and analgesia in the Pediatric Intensive Care Unit]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tobias]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
</person-group>
<source><![CDATA[Pediatric Annals]]></source>
<year>2005</year>
<volume>34</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>636-45</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The pharmacokinetics of midazolam in man]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Eadie]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[O'Rourke Brophy]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<source><![CDATA[Eur J Clin Pharmacol]]></source>
<year>1981</year>
<volume>19</volume>
<page-range>271-8</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Midazolam a review of its pharmacological properties and therapeutic use]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dundee]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
<name>
<surname><![CDATA[Halliday]]></surname>
<given-names><![CDATA[NJ]]></given-names>
</name>
<name>
<surname><![CDATA[Harper]]></surname>
<given-names><![CDATA[KW]]></given-names>
</name>
</person-group>
<source><![CDATA[Drugs]]></source>
<year>1984</year>
<volume>28</volume>
<page-range>519-43</page-range></nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The cytochrome P450 system and adverse drug reactions]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shenfield]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Gross]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Adv Drug React Bull]]></source>
<year>1999</year>
<volume>194</volume>
<page-range>739-42</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Serrano Espinosa]]></surname>
<given-names><![CDATA[VG]]></given-names>
</name>
</person-group>
<source><![CDATA[Estudio observacional del uso de midazolam genérico en el Instituto Oncológico Nacional de Panamá, para la sedación consciente en pacientes sometidos a gastroscopia]]></source>
<year>2005</year>
<publisher-loc><![CDATA[Barcelona, España ]]></publisher-loc>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
